Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Aeglea BioTherapeutics, Inc. (AGLE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
10/05/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "Aeglea BioTherapeutics, Inc. Condensed Consolidated Balance Sheets June 30, December 31, 2023 2022 ASSETS CURRENT ASSETS Cash and cash equivalents $ 235,358 $ 34,863 Marketable securities — 20,848 Development receivables 1,646 375 Prepaid expenses and other current assets 2,882 6,172 Total current assets 239,886 62,258 Restricted cash 1,317 1,553 Property and equipment, net — 3,220 Operating lease right-of-use assets 2,316 3,430 Other non-current assets 10 683 TOTAL ASSETS $ 243,529 $ 71,144 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable $ 2,854 $ 677 Forward contract liability 164,382 — CVR liability 10,500 — Operating lease liabilities 4,331 625 Deferred revenue 930 517 Accrued and other current liabilities 28,427 12,837 Related party accounts payable 20,810 — ..."
08/11/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/07/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/07/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/28/2023 SC 13G Polar Capital Holdings Plc reports a 5% stake in AEGLEA BIOTHERAPEUTICS, INC.
07/27/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma"
07/18/2023 SC 13G Logos Global Management LP reports a 8.1% stake in Aeglea Biotherapeutics, Inc.
07/14/2023 8-K Quarterly results
07/10/2023 SC 13G Venrock Healthcare Capital Partners III, L.P. reports a 10% stake in Aeglea BioTherapeutics, Inc.
07/06/2023 D Form D - Notice of Exempt Offering of Securities:
07/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/30/2023 SC 13D Fairmount Funds Management LLC reports a 20% stake in AEGLEA BIOTHERAPEUTICS, INC.
06/30/2023 SC 13G EcoR1 Capital Fund Qualified, L.P. reports a 6.4% stake in Aeglea Biotherapeutics, Inc.
06/30/2023 SC 13G Deep Track Capital, LP reports a 10% stake in AEGLEA BIOTHERAPEUTICS, INC.
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/19/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results $39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023"
04/25/2023 8-K Quarterly results
04/17/2023 ARS Form ARS - Annual Report to Security Holders:
04/17/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/13/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Investor presentation, Quarterly results
Docs: "Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates Jeffrey Goldberg, experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 million of cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022, which is expected to fund operations into the fourth quarter of 2023",
"7.0 14.0 21.5 36.0 ER FR PR NR"
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 7.5% stake in AEGLEA BIOTHERAPEUTICS, INC.
02/14/2023 SC 13G/A ORBIMED ADVISORS LLC reports a 2.9% stake in Aeglea BioTherapeutics, Inc.
02/14/2023 SC 13G BAKER BROS. ADVISORS LP reports a 9.9% stake in Aeglea BioTherapeutics, Inc.
02/14/2023 SC 13G Rock Springs Capital Management LP reports a 5.6% stake in AEGLEA BIOTHERAPEUTICS, INC.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy